Medical Journal Features Clinical Study of BioTime's Plasma Expander.Business Editors & Health/Medical Writers BIOWIRE2K BERKELEY, Calif.--(BW HealthWire)--Jan. 9, 2002 BioTime, Inc. (AMEX AMEX See: American Stock Exchange :BTX (Balanced Technology EXtended) A motherboard design from Intel introduced in 2004 that supersedes the ATX. Unlike the ATX, the placement of all chip sockets in the BTX is defined in order to provide sufficient air flow over the processor and display adapter. ) announced today that a front page article in the December 2001 issue of Anesthesiology News, vol. 27, no. 12, (www.anesthesiologynews.com) a medical journal received by most anesthesiologists in the United States, highlighted the importance of "balanced" surgical fluids used to replace lost blood volume. Balanced surgical fluids are considered to be those with a comprehensive composition containing a variety of electrolytes and other components present in blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. , rather than simply formulated with saline. The article described the results of a prospective, randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double-blinded clinical study recently completed at New York's Columbia University involving 200 patients. The study included four groups of patients, each group receiving a different surgical fluid. It focused on a variety of physiological indices, including those used to measure kidney function. Other recently published articles have demonstrated the importance of balanced formulations in plasma expanders and surgical fluids. The September 2001 issue of Anesthesia & Anesthesia included a study at the Royal Free and University College Medical School The Royal Free and University College Medical School (RFUCMS) is the medical school of University College London. It was formed in 1998 following a series of mergers between a number of existing medical schools: in 1987 the Middlesex Hospital Medical School (founded 1746) merged , London, UK (Wilkes, NJ et al., Anesth Analg 2001;93; 811-6) focusing on the impact of balanced versus saline-based fluids on acid-base equilibrium and blood biochemistry. "It is gratifying grat·i·fy tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies 1. To please or satisfy: His achievement gratified his father. See Synonyms at please. 2. to see the growing recognition that it is important to replace lost blood volume with fluids that more closely resemble the composition of blood plasma, especially when the volumes replaced are large," said Dr. Paul Segall, BioTime chairman and chief executive officer. "BioTime's plasma expander is one of the fluids tested in both of these studies. It is the only plasma volume expander containing hetastarch, multiple electrolytes, lactate Lactate A salt or ester of lactic acid (CH3CHOHCOOH). In lactates, the acidic hydrogen of the carboxyl group has been replaced by a metal or an organic radical. Lactates are optically active, with a chiral center at carbon 2. and physiological amounts of glucose. It is a proprietary product approved for use in replacing blood volume lost during surgery." BioTime's product is currently used in hundreds of leading hospitals in the United States Lists of hospitals for each U.S. state:
BioTime, headquartered in Berkeley, California develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Information about BioTime can be found on the web at www.biotimeinc.com. The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of BioTime products; BioTime's ability to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and foreign regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime's products; BioTime's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in BioTime products; the availability of reimbursement for the cost of BioTime products (and related treatment) from government health administration authorities, private health coverage insurers and other organizations; and the ability of BioTime to raise additional capital. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion